Please assess the completion status of the following clinical trial:

Trial Title: Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 15 years and older in Colorado and 19 years and older in Nebraska. A waiver of parental consent is planned for individuals 15-17 in accordance with Colorado law which allows minors to consent for treatment for sexually transmitted infections, including HIV.~* Reactive HIV-1 on an approved fourth generation HIV-1 antibody/antigen test within 72 hours~* Any primary language with access to an interpreter by phone is included.~Exclusion Criteria:~* Pregnancy or intention to become pregnant in the next two years after enrollment~* Symptomatic acute HIV (with fever, rash, influenza-like symptoms)~* Creatinine clearance \<30 mL/min by Cockcroft-Gault equation. (Therapy initiated will be terminated promptly in individuals who are found to have creatinine clearance \<30 mL/min)~* Prior history of known HIV diagnosis~* Negative confirmatory HIV differentiation assays (therapy initiated will be terminated in individuals with negative tests and excluded from the primary analysis)~* Allergy to bictegravir, emtricitabine or tenofovir alafenamide~* Signs or symptoms of opportunistic infection with cryptococcal meningitis, tuberculosis or other infection that requires delay of initiation of antiretroviral therapy (up to the discretion of the site PI)~* Vulnerable populations including prisoners and individuals without decision making capacity~* Concommitant use of medications that are contraindicated with bictegravir, emtricitabine and tenofovir alafenamide including adefovir, carbamazepine, cladribine, dofetilide, fosphenytoin-phenytoin, oxcarbazepine, phenobarbital, primidone, rifampin, rifabutin, rifapentine, St. John's Wort, tipranavir

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Rapid Start Group (Type: ACTIVE_COMPARATOR): Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
- Arm B: Standard Group (Type: PLACEBO_COMPARATOR): Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.

Based on this trial design, predict the completion outcome and termination type (if applicable).